BALTIMORE, Feb. 2 /PRNewswire/ -- Lentigen Corporation announced today that the State of Maryland has recognized it as one of the recipients of the first Maryland Technology Champions Awards. Maryland Governor Robert L. Ehrlich, Jr. and Secretary Aris Melissaratos presented the Governor's Citation at a reception at the Maryland State House on January 31, 2006.
Nominations for this award were provided by the Maryland Department of Economic Development, in addition to service providers and other strategic partners assisting technology companies headquartered in Maryland. The program's founding partners are The Tech Council of Maryland, the Gazette of Politics & Business and BDO Seidman, LLP. Key supporters are ADP Corp., HarVest Bank of Maryland, Invest Northern Ireland and Pillsbury Law.
Dr. Boro Dropulic, Founder and CEO of Lentigen, remarked, "It is quite an honor to be recognized by the Governor's Office as one of the top new technology companies in terms of success and growth in Maryland. We're committed to building our biotechnology business here in Maryland to serve customers around the globe."
About Lentiviral Vectors
Lentiviral vectors (LV) are vehicles that can deliver genes or RNAi into cells with up to 100% efficiency and stability. By comparison, other viral vector systems such as non-viral, adenoviral and adeno-associated viral vectors have not been shown to achieve both high and stable gene delivery in dividing cells.
Gene delivery is accomplished by the binding and fusing of the LV pseudotyped envelope protein to the target cell membrane. The LV RNA containing the gene or gene silencing sequence is then incorporated into the cell via reverse transcription creating a DNA complex. This complex enters the nucleus incorporating into the chromosomal DNA creating a stable molecule. The gene sequence is integrated in the chromosome and is copied along with the DNA during ongoing cell division.
About Lentigen Corporation
Lentigen Corporation is a privately owned biotechnology company focused on the manufacturing and development of lentiviral vectors using its proprietary gene delivery technology for a wide range of applications in biotechnology and medicine. Lentiviral vectors are highly adapted delivery vehicles that can transport genes or gene silencing sequences into cells with high efficiency and stability. Lentigen is positioning itself to become the leading provider of Lentiviral vector products and services for academic, government, biotechnology and pharmaceutical researchers. For further information, visit http://www.Lentigen.com.
Lentigen CorporationCONTACT: Greg Feulner, VP Business Development of Lentigen Corporation,+1-443-543-5318, greg.feulner@lentigen.com; or Media - Gregory Tiberend ofRichard Lewis Communications, Inc., +1-212-827-0020, gtiberend@rlcinc.com,or Investor - Tara Spiess of TS Communications Group, LLC, +1-914-921-5900,spiess@biotechirpr.com, both of Lentigen Corporation
Web site: http://www.Lentigen.com/
